A Novel TPD Platform Leveraging a New E3 Ligase to Minimize Hematologic Toxicity
- Introduction of a novel TPD platform with a differentiated profile based on a new E3 ligase
- Data highlighting efficient target degradation with reduced hematologic off-target effects
- Insights into strategies to mitigate toxicity risk in future TPD development